Seibel M J, Woitge H, Scheidt-Nave C, Leidig-Bruckner G, Duncan A, Nicol P, Ziegler R, Robins S P
Department of Internal Medicine, University of Heidelberg, Germany.
J Bone Miner Res. 1994 Sep;9(9):1433-40. doi: 10.1002/jbmr.5650090916.
The urinary pyridinium crosslinks pyridinoline (PYD) and deoxypyridinoline (DPD) have been shown to provide valid indices of bone resorption. At present, both crosslink components are determined by reversed-phase HPLC, a time-consuming method precluding the use of these markers for routine purposes. Therefore, efforts have been made to develop simple immunoassays for the rapid measurement of urinary crosslinks, and their application to large-scale osteoporosis screening has been proposed. To evaluate the applicability and diagnostic validity of pyridinium crosslink measurements for screening purposes, urinary concentrations of total and free PYD and DPD were determined by HPLC and immunoassay technique (ELISA) in a sample of 269 individuals (male to female ratio = 130:139; age 50-81 years) recruited at random within a population survey of vertebral osteoporosis. On a molar basis, ELISA measures of crosslink-related epitopes were highly correlated with both total and free PYD and DPD as determined by HPLC (r > 0.82, p < 0.001). Age-specific means for creatinine-corrected total and free pyridinium crosslinks were significantly higher in females than in males (p < 0.001). In both sexes, neither age nor anthropometric variables (weight, height, and body mass index) showed a linear effect on the urinary crosslink/creatinine ratio. On average, 50% of the total amount of urinary crosslinks were present in free form. For both PYD and DPD, this proportion was significantly higher in women than in men (p < 0.05), but no change was observed with age or anthropometric measures. The excretion of pyridinium crosslinks was higher in osteoporotic (n = 18) than in nonosteoporotic individuals (n = 208) from the same population.(ABSTRACT TRUNCATED AT 250 WORDS)
尿吡啶交联物吡啶啉(PYD)和脱氧吡啶啉(DPD)已被证明可提供有效的骨吸收指标。目前,两种交联成分均通过反相高效液相色谱法测定,这是一种耗时的方法,妨碍了这些标志物用于常规目的。因此,人们致力于开发简单的免疫测定法以快速测量尿交联物,并有人提出将其应用于大规模骨质疏松症筛查。为了评估吡啶交联物测量用于筛查目的的适用性和诊断有效性,在一项椎体骨质疏松症人群调查中随机招募了269名个体(男女性别比 = 130:139;年龄50 - 81岁),通过高效液相色谱法和免疫测定技术(酶联免疫吸附测定法)测定了尿中总PYD、游离PYD以及总DPD、游离DPD的浓度。以摩尔为基础,酶联免疫吸附测定法测得的交联相关表位与高效液相色谱法测定的总PYD、游离PYD以及总DPD、游离DPD均高度相关(r > 0.82,p < 0.001)。经肌酐校正后的总吡啶交联物和游离吡啶交联物的年龄特异性均值在女性中显著高于男性(p < 0.001)。在两性中,年龄和人体测量变量(体重、身高和体重指数)均未对尿交联物/肌酐比值呈现线性影响。平均而言,尿交联物总量的50%以游离形式存在。对于PYD和DPD,该比例在女性中显著高于男性(p < 0.05),但未观察到随年龄或人体测量指标的变化。来自同一人群的骨质疏松症患者(n = 18)的吡啶交联物排泄量高于非骨质疏松症个体(n = 208)。(摘要截断于250字)